Epstein Barr virus : one herpes virus : many diseases
Author(s)
Bibliographic Information
Epstein Barr virus : one herpes virus : many diseases
（Current topics in microbiology and immunology, 390-391）
Springer, c2015
- v. 1
- v. 2
Available at / 7 libraries
-
No Libraries matched.
- Remove all filters.
Note
Includes bibliographical references and index
Description and Table of Contents
- Volume
-
v. 1 ISBN 9783319228211
Description
Epstein Barr virus (EBV) was discovered as the first human tumor virus around 50 years ago. Since its discovery in Burkitt's lymphoma it has been associated with various other malignancies, infectious mononucleosis and even autoimmune diseases. The two book volumes on EBV summarize the first 50 years of research on this tumor virus, starting with historical perspectives on discovery, oncogenicity and immune control, reviewing the role that the virus plays in the various associated diseases and concluding with a discussion on how the immune system keeps persistent EBV infection under control in healthy EBV carriers and can be used to treat EBV associated diseases. The respective 32 chapters are written by international experts from three continents for health care providers, biomedical researchers and patients that are affected by EBV. The assembled knowledge should help to understand EBV associated diseases better and to develop EBV specific vaccination in the near future.
Table of Contents
Preface.- History.- Chap. 1 Why and How Epstein-Barr Virus was discovered 50 years ago - Anthony Epstein, University of Oxford, UK.- Chap. 2. Tumor associations of EBV - historical perspectives - George Klein, Karolinska Institutet, Stockholm, Sweden.- Chap. 3. EBV-specific immune response: early research and personal reminiscences - Denis J. Moss and Viviana P. Lutzky, Queensland Institute of Medical Research, Brisbane, Australia.- Virus genetics and epigenetics.- Chap. 4. Epstein Barr virus strain variation - Paul J. Farrell, Imperial College, London, UK.- Chap. 5. Chromatin Structure of Epstein-Barr Virus Latent Episomes - Paul M. Lieberman, University of Pennsylvania, Philadelphia, USA.- Chap. 6. The epigenetic life cycle of Epstein-Barr virus - Wolfgang Hammerschmidt, Helmholtz Center Munich, Germany. Chap. 7. Epstein-Barr virus: from the detection of sequence polymorphisms to the recognition of viral types - Regina Feederle, Olaf Klinke, Anton Kutikhin, Remy Poirey, Ming-Han Tsai and Henri-Jacques Delecluse, German Cancer Research Center, Heidelberg, Germany.- Viral infection and associated diseases.- Chap. 8. EBV persistence - introducing the virus - David A. Thorley-Lawson, Tufts University, Boston, USA.- Chap. 9. Infectious mononucleosis - Samantha K. Dunmire, Kristin A. Hogquist and Henry H. Balfour, Jr., University of Minnesota, Minneapolis, USA.- Chap. 10. Primary immunodeficiencies associated with EBV disease - Jeffrey I. Cohen, National Institutes of Health, Bethesda, USA.- Chap. 11. Burkitt's lymphoma - Rosemary Rochford and Ann M. Moormann, University of Massachusetts, Worcester, and Upstate University of New York, Syracuse, USA.- Chap. 12. Contribution of the Epstein-Barr virus to the pathogenesis of Hodgkin lymphoma - Paul Murray and Andrew Bell, University of Birmingham, UK.- Chap. 13. The role of EBV in the pathogenesis of diffuse large B cell lymphoma - Jane A. Healy and Sandeep S. Dave, Duke University, Raleigh, USA.- Chap. 14. Nasopharyngeal carcinoma: an evolving role for the Epstein Barr virus - Nancy Raab-Traub, University of North Carolina, Chapel Hill, USA.-Chap. 15. EBV and autoimmunity - Alberto Ascherio and Kassandra Munger, Harvard University, Boston, USA.- Index.
- Volume
-
v. 2 ISBN 9783319228334
Description
Epstein Barr virus (EBV) was discovered as the first human tumor virus around 50 years ago. Since its discovery in Burkitt's lymphoma it has been associated with various other malignancies, infectious mononucleosis and even autoimmune diseases. The two book volumes on EBV summarize the first 50 years of research on this tumor virus, starting with historical perspectives on discovery, oncogenicity and immune control, reviewing the role that the virus plays in the various associated diseases and concluding with a discussion on how the immune system keeps persistent EBV infection under control in healthy EBV carriers and can be used to treat EBV associated diseases. The respective 32 chapters are written by international experts from three continents for health care providers, biomedical researchers and patients that are affected by EBV. The assembled knowledge should help to understand EBV associated diseases better and to develop EBV specific vaccination in the near future.
Table of Contents
Preface.- EBV latency.- Chap. 1. EBNA1 - Lori Frappier, University of Toronto, Canada.- Chap. 2. EBNA2 and its coactivator EBNA-LP - Bettina Kempkes, Helmholtz Center Munich, Germany, and Paul D. Ling, Baylor College of Medicine, Houston, USA.- Chap. 3. The EBNA3 family: two oncoproteins and a tumour suppressor that are central to the biology of EBV in B cells- Martin J. Allday, Quentin Bazot and Robert E. White, Imperial College London, UK. Chap. 4. The latent membrane protein 1 (LMP1) - Arnd Kieser and Kai R. Sterz, Helmholtz Center Munich, Germany. Chap. 5. Latent membrane protein 2 (LMP2) - Osman Cen and Richard Longnecker, Northwestern University, Chicago, USA. Chap. 6. EBV non-coding RNAs - Rebecca L. Skalsky and Bryan R. Cullen, Duke University, Durham, USA.- E. Lytic EBV infection.- 7. Viral entry - Liudmila S. Chesnokova, Ru Jiang1 and Lindsey M. Hutt-Fletcher, Louisiana State University, Shreveport, USA.- Chap. 8. Epstein Barr virus lytic cycle reactivation - Jessica McKenzie and Ayman El-Guindy, Yale University, New Haven, USA.- Immune responses to EBV.- Chap. 9. Innate immune recognition of EBV - Anna Lunemann and David Nadal, University of Zurich, Switzerland and Martin Rowe, University of Birmingham, UK.- Chap. 10. Epstein-Barr virus specific humoral immune responses in health and disease - Jaap M. Middeldorp, VU Medical Center, Amsterdam, The Netherlands.- Chap. 11. T cell responses to EBV - Andrew D. Hislop and Graham S. Taylor, University of Birmingham, UK.- Chap. 12. Immune evasion by Epstein Barr virus - Maaike E. Ressing, Michiel van Gent, Anna M. Gram, Marjolein Hooykaas, Sytse Piersma and Emmanuel Wiertz, Utrecht Medical Center, The Netherlands.- Animal models of EBV infection.- Chap. 13. Non-human primate lymphocryptoviruses: past, present, and future- Janine Muhe and Fred Wang, Harvard University, Boston, USA. Chap.14. EBV infection of mice with reconstituted human immune system components -
Christian Munz, University of Zurich, Switzerland.- Therapy of EBV associated diseases.- Chap. 15. Adoptive T cell immunotherapy - Stephen Gottschalk and Cliona Rooney, Baylor College of Medicine, Houston, USA.- Chap. 16. The Development of Prophylactic and Therapeutic EBV Vaccines - Corey Smith and Rajiv Khanna, Queensland Institute of Medical Research, Brisbane, Australia.- Chap. 17. The biology and clinical utility of EBV monitoring in blood- Jennifer Kanakry and Richard Ambinder, Johns Hopkins University, Baltimore, USA.- Index.
by "Nielsen BookData"
